The pharmaceutical giant, which has nearly $35 billion of debt, is aiming to reduce costs by $1.5 billion to $2 billion in the next two years. A little less than half of the cost reductions would come from cuts in research and development spending.
While a decision has not yet been made on the number of layoffs, a range of 5,000 to 10,000, or about 15 percent of its workforce is being discussed, according to the report. It is not clear which locations would be affected.
At the end of 2016, the drugmaker employed nearly 57,000 people globally — including more than 10,000 in the U.S., 24,000 in Europe and 6,800 in Israel.
More articles on supply chain:
Philippine government to seek $59M refund, sue Sanofi over dengue vaccine risks
Gilead to acquire Cell Design Labs for up to $567M
Merck to shutter facility in South Carolina, lay off 50 employees
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
